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ABSTRACT
High-throughput, microarray-based chromatin
immunoprecipitation (ChIP-chip) technology allows
in vivo elucidation of transcriptional networks.
However this complex is not yet readily accessible,
in part because its many parameters have not
been systematically evaluated and optimized.
We address this gap by systematically assessing
experimental-design parameters including antibody
purity, dye-bias, array-batch, inter-day hybridiza-
tion bias, amplification method and choice of
hybridization control. The combined performance
of these optimized parameters shows a 90% vali-
dation rate in ChIP-chip analysis of Myc genomic
binding in HL60 cells using two different microarray
platforms. Increased sensitivity and decreased
noise in ChIP-chip assays will enable wider use
of this methodology to accurately and affordably
elucidate transcriptional networks.
INTRODUCTION
The combination of chromatin immunoprecipitation
(ChIP) and high-throughput DNA microarray technol-
ogy (chip) provides a powerful method (ChIP-chip) for
mapping protein–DNA interactions in vivo. The ChIP-
chip procedure was first used to study yeast transcription
factors (1–4) and has recently been exploited for similar
studies in mammalian cells (5–15). In the ChIP-chip
procedure, genomic DNA is precipitated using specific
and control antibodies, then labeled and hybridized to
genomic microarrays. Several different array platforms
have been used, including proximal promoter region
arrays (11), CpG island arrays (12,15) and whole-
genome tiling arrays (16,17). The technique is extremely
versatile and can identify target genes whose regulatory
regions are bound by transcription factors through both
protein–DNA and protein–protein interactions. ChIP-
chip can be applied to any cell or tissue, making it possible
to decode gene regulatory networks in vivo. Certainly, the
ability to profile bona fide target genes has been revolu-
tionized by ChIP-chip. Unlike mRNA expression analysis,
the genetic program specifically directed by the transcrip-
tion factor can be distinguished from subsequent down-
stream regulatory events (18–22).
Although ChIP-chip has become the standard for
discovering the genomic binding sites of transcriptional
regulators there is wide variability in experimental
design (23). This variability has complicated and delayed
widespread application, and is a reflection of the large
number of parameters that must be carefully optimized
in ChIP-chip experiments. For example, the number of
cells or amount of tissue used as starting material varies
widely from one study to another (24,25). The protein–
protein and/or protein–DNA cross-linking, chromatin
sonication, as well as antibody sensitivity and purity
characteristics can also vary significantly. In most studies,
the enriched DNA recovered after the ChIP procedure is
amplified. A variety of amplification methods have been
developed, including ligation-mediated PCR (25,26),
random primed PCR (27), T7 primed PCR (28) and
Whole Genome Amplification (WGA) (29), and it is
unclear which method is most appropriate for ChIP
studies. Finally, when the amplified and labeled DNA
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is hybridized to a microarray a control sample must be
selected and the effects of array batch and dye-swap status
considered.
Experimental design parameters for mRNA expression
arrays have been extensively evaluated by a number of
groups over the past decade (30–36). As a result, the key
factors are well understood and the assay has been opti-
mized. It is possible, for example, to estimate the number
of biological replicates required to sufficiently power
a specific hypothesis-testing question (37). Despite this
clear evidence that parameter optimization can greatly
improve the quantity and quality of information retrieved
from an array analysis, ChIP-chip design parameters
have not yet been thoroughly and systematically inves-
tigated, and it cannot be assumed that parameters and
processes would be the same for both mRNA and ChIP-
chip arrays.
Here, we fill that gap by providing a comprehensive
evaluation of experimental design parameters for ChIP-
chip studies. Through a series of validation studies we
address both the parameters previously investigated for
mRNA expression studies as well as those specific to
ChIP-chip experiments. We exploit a well-characterized
system: the genomic binding of the Myc oncoprotein
in HL60 cells, a human myelogenous leukemia cell line,
combined with CpG island arrays (38). Many parameters
for successful ChIP-chip studies were analyzed, including
antibody purity, array batch variability, dye-bias, inter-
day hybridization-variability, amplification procedure
and hybridization control. In addition, we evaluated the
combined effect of the optimized parameters by conduct-
ing a Myc ChIP-chip study using an alternative oligonu-
cleotide array platform. Our results show a high rate of
validation by real time Q-PCR. The raw data from this
study, encompassing over 100 arrays has been deposited in
the Gene Expression Omnibus (GEO) repository at NCBI.
Our careful description of ChIP-chip experimental design
is a key step towards enabling widespread use of this
important technology for the rapid elucidation of global
transcriptional regulatory networks.
MATERIALS AND METHODS
Antibody production and purification
The DNA fragment corresponding to the Myc 1-262N-
terminal domain polypeptide was cloned into pET15b
vector (Novagen 69661-3) at 50-NdeI and 30-BamHI sites.
His-c-Myc (1–262) fusion protein was purified under dena-
tured conditions using Talon beads (BD Biosciences,
Mississauga, ON, Canada). His-c-Myc (1–262) fusion pro-
tein was purified under denatured conditions using Talon
beads (BD Biosciences) as follows, the cell pellet was
homogenized in 40ml of lysis buffer pH 8.0 (5mM imi-
dazole, 20mM Tris, 500mM NaCl, 10 mM ZnCl2, 6M
Guanidine hydrochloride, 0.1% Triton X-100, 1mM
b-mercaptoethanol) and sonicated three times for 3min
at duty cycle 30 and 30% output. The lysate was then
centrifugated at 14 000 r.p.m. for 30min at 48C. Next,
4ml of 50% Talon beads were washed with 50ml of
binding buffer pH 8.0 (lysis buffer without TX-100) and
pelleted at 1800 r.p.m. for 5min. The lysed supernatant
was incubated with washed Talon beads with gentle swirl-
ing for 1 h at room temperature and then centrifugated at
1800 r.p.m. for 5min at 48C. The beads were washed once
with binding buffer and once with washing buffer pH 8.0
(Binding buffer with 10mM imidazole). The proteins were
eluted by adding 1ml of elution buffer pH 8.0 (binding
buffer with 500mM imidazole) to the beads and after cen-
trifugation at 1800 r.p.m. for 5min at 48C the supernatant
was collected. The protein concentration is checked and
the elution step is repeated several times until no more or
very low protein is detected. The purity of the protein
sample is then checked by SDS–PAGE. The denatured
protein sample was precipitated by adding 900 ml of 95%
ethanol to 100 ml of protein sample, and then centrifugated
at 14 000 r.p.m. for 10min. The pellet was resuspended in
20 ml of SDS-loading buffer before loading. The purified
protein was concentrated to 2.8mg/ml before injecting
into the rabbit. The purified protein was then dissolved
in a volume of 500 ml of PBS per rabbit. Primary immu-
nizations were done with 500 mg of purified protein per
rabbit. First boost was done with 250 mg of purified pro-
tein. Two subsequent boosts were done with 50 mg of
purified protein. The final bleed was then purified using
Enchant IgG Purification Kit with Protein A, IgG Purifi-
cation (Pall 5300-IGGPROA) as follows: the sample was
diluted 1:1 with binding buffer and applied to the equili-
brated Protein A affinity column. The column was washed
once with the Protein A Binding Buffer and then eluted
with the Protein A Elution Buffer to recover the bound
IgG. Each microliter of purified fraction was then neu-
tralized by adding 50 ml of 1M Tris, pH 9.5.
Cell culture conditions
HL60 (ATCC) cells were maintained in a-MEM with
10% FBS.
Chromatin immunoprecipitation
Exponentially growing HL60 cells were cross-linked with
1% formaldehyde for 10min at 378C. The cross-linking
reaction was quenched by addition of glycine to a final
concentration of 0.125M for 5min, followed by two
washes with phosphate-buffered saline (PBS). Cells were
resuspended in cell lysis buffer (5mM PIPES pH 8, 85mM
KCl, 0.5% [v/v] NP40, 1mM PMSF, 10 mg/ml aprotinin,
10 mg/ml leupeptin) for 10min on ice and then pelleted
(5000 r.p.m., 5min, 48C). The pellet was resuspended in
1ml of nuclei lysis buffer (50mM Tris–HCl pH 8.1,
10mM EDTA, 1% SDS, 1mM PMSF, 10 mg/ml aprotinin,
10 mg/ml leupeptin) for 10min on ice and then sonicated
using 8 pulses (12–13 Watts, setting 10, 10 s per pulse,
45 s on ice between pulses) from a Model 60 Sonic
Dismembrator (Fisher Scientific 15-338-53) to generate
fragments between 600 bp and 1000 bp. Lysates were
centrifuged for 10min at 21 000g at 48C. Supernatants
were diluted into an equal volume with IP dilution
buffer (0.01% SDS, 1.1% Triton-X100, 1.2mN EDTA,
16.7mM Tris–HCl pH 8.1, 0.2% Sarkosyl, 1mM
PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin) and
precleared for 30min at 48C with protein G-PLUS
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agarose beads (Santa Cruz Biotechnology, Santa Cruz,
CA, USA, sc-2002). Prior to use, G-PLUS agarose beads
were blocked with salmon sperm DNA at a final concen-
tration of 50 mg/ml and rotated overnight at 48C. Diluted
and cleared extracts corresponding to 10 x 106 HL60 cells
were incubated and rotated at 48C for 12–16 h with each
of the following antibodies: no-antibody control, 0.7mg
normal rabbit IgG (Santa Cruz Biotechnology sc-2027),
0.7 mg N262 (Santa Cruz Biotechnology sc-764), for the
N262 home-made unpurified and purified antibodies, we
determined empirically, by serial dilutions, the amount of
antibody to be used. A 50 ml of salmon sperm DNA pre-
blocked Protein G-PLUS agarose beads were added to
each sample, incubated on a rotating platform at 48C for
3 h. Each pellet was washed once with 1.4ml of sonica-
tion buffer and then twice with 1.4ml of high salt buffer
(0.1% [v/v] SDS, 1% [v/v] Triton X-100, 1mM EDTA,
50mM HEPES, 500mM NaCl, 0.1% [w/v] sodium
deoxycholate) and then once with 1.4ml LiCl Buffer
(250mM LiCl, 1% [v/v] NP-40, 1% [w/v] sodium deoxy-
cholate, 1mM EDTA, 1mM Tris pH 8) and finally twice
with 1.4ml TE pH 8 (10mM Tris pH8, 1mM EDTA).
For each wash, the pellets were mixed for 5min at room
temperature then pelleted (3000 r.p.m., 30 s, room tem-
perature). After the last wash, the pellets were eluted in
300 ml of Elution buffer (1% [w/v] SDS, 10mM Tris pH 8,
5mM EDTA), incubated at 658C for 15min, and then
pelleted (3000 r.p.m., 3min, room temperature). Cross-
links were reversed in the presence of 200mM NaCl at
658C over-night and samples were treated with RNase A
(Sigma R5500). After ethanol precipitation, the samples
were resuspended in 100 ml of TE (10mM Tris, pH 7.5,
1mM EDTA), 25 ml of 5 proteinase K buffer (1.25%
SDS, 50mM Tris, pH 7.5, 25mM EDTA), and 1.5ml of
proteinase K (Roche 1413783) and incubated at 428C
for 2 h. DNA was extracted from each sample using
phenol:chloroform:isoamyl alcohol (25:24:1), then pre-
cipitated with 1/10th volume of 3M sodium acetate
(pH 5.3), 5 mg of glycogen, and 2 volumes of ethanol at
208C overnight. Pellets were collected by microcentrifu-
gation and resuspended in 60 ml of H2O.
PCR
A total of 2 ml of the ChIP DNA was PCR amplified using
promoter-specific primers. All PCR primers (synthesized
by Sigma Genosys, Oakville, ON, Canada or Invitrogen,
Burlington, ON, Canada) were resuspended in sterile
RNase-/DNase-free water. In general, each 10 ml PCR
reaction, set up at room temperature, was composed of
10 ng/ml of each primer (fwd/rev), 1 PCR buffer, 0.2mM
dNTP mix, sterile water, DNA template and 0.2ml
HotstarTaq DNA polymerase (Qiagen, Mississauga,
ON, Canada, 203205); the HotstarTaq was activated
by initiating the PCR program at 958C for 15min.
Amplification of each PCR primer set was performed
using multiple annealing temperatures along a 52–688C
gradient for 30 s. Primer sequences are provided in
Supplementary Table 8. All PCR reactions were electro-
phoresed on 100ml 1.2% agarose gels containing 4 ml
of 10mg/ml EtBr, and then visualized by UV florescence.
Real-time quantitative PCR
Real-time quantitative PCR (Q-PCR) amplification was
conducted using the SYBR Green assay in the ABI
PRISM 7900-HT (Applied Biosystems, Foster City, CA,
USA). Each 12ml quantitative PCR reaction was composed
of the following: 2ml of the DNA isolated in the ChIP, 1x
PCR Buffer, 2.5mM MgCl2, 0.17mM dNTP mix, sterile
water, 0.25 SYBR Green (Sigma S9430), 0.2ml Rox refer-
ence dye (Invitrogen 12223-012) and 0.05ml Platinum Taq
DNA polymerase (Invitrogen 10966-034) and was per-
formed in triplicate in a 384-well plate. The reactions
began at 508C for 2min and then were activated at 958C
for 10min followed by 40 cycles of 958C for 15 s and 608C
for 1min. Human male genomic DNA (Novagen 70572)
was used as standard real-time Q-PCR was conducted in
triplicates for each of the three independent biological
replicates. The Q-PCR data were analyzed by calculating
theMyc/IgG ratios for each target gene, and the Chr6 nega-
tive control. A symmetrical distribution was then obtained
by log2-transformation of each individual ratio. Statistical
testing involved comparison of the ratios for each target
gene to the ratios of the Chr6 negative control using a
two-tailed paired t-test. Primer sequences are provided in
Supplementary Table 8. The primers were designed using
Primer Express Software Version 2.0 (Applied Biosciences)
with the following parameters: Tm range of 58–608C, the
primer length between 19 and 50bp, optimal primer
length of 20 bases, and amplicon length of 80–200bp.
Random primer PCR amplification methods
The immunoprecipitated DNA was amplified as described
elsewhere (www.microarrays.ca/support/PDFs/ChIP_
Protocol_for_Microarray_Analysis_Beads_corr_01-12-06.
pdf) with the following modifications: 15 ml of Round A
are mixed with Round B1 Reaction Mix to a final volume
of 100 ml [4 ml of 50mM MgCl2, 10 ml of 10 PCR Buffer,
2 ml of 10mM dNTPs, 2.5 ml of 100 mM of Primer B
(50GTTTCCCAGTCACGATC30), 1 ml of Taq DNA Poly-
merase (Promega, Madison, WI, USA, M1861)]. Amplifi-
cation/Nucleotide Incorporation Program: (948C for 30 s,
408C for 30 s, 508C for 30 s, 728C for 1min) 20 cycles,
728C for 2min.
A total of 15 ml of Round B1 were mixed with Round
B2 Reaction Mix to a final volume of 50 ml [2ml of 50mM
MgCl2, 5 ml of 10 PCR Buffer, 0.5 ml of dNTP Mix B2
(25mM of dATP, dCTP, dCTP, 12.5mM dTTP), 1.5 ml
of 2mM aa-dUTP, 1 ml of 100 mM of Primer B
(50GTTTCCCAGTCACGATC30), 1 ml of Taq DNA
Polymerase (Promega M1861)]. Amplification/Nucleotide
Incorporation Program: (928C for 30 s, 408C for 30 s,
508C for 30 s, 728C for 1min) 15 cycles, 728C for
2min. Round B2 amplified DNA was concentrated
using Microcon columns (Millipore, Billerica, MA,
USA, Microcon YM-30). Once the ChIP DNA was
amplified to 3 mg, PCR reactions were performed with
10 ng amplified DNA and were identical to the reac-
tions performed after the ChIP DNA was initially
isolated. This PCR was used to determine whether
specificity between the IgG or NoAb and antibody
samples was maintained after the amplification.
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Ligation-mediated PCR amplification
The DNA from each ChIP reaction was treated as
described elsewhere (26). The PCR was performed using
the following cycling protocol: 1 cycle of 558C for
2min, 728C for 5min, and 958C for 2min and the corre-
sponding number of cycles for ligation-mediated PCR
(LM-PCR) A and LM-PCR B (see below LM-PCR A
and B cycle conditions) at 958C for 30 s, 558C for 30 s
and 728C for 1min, ending with 4min at 728C and then
an endless cooling at 48C. After the PCR, the DNA was
again isolated using the QIAquick PCR purification kit
(Qiagen 28106). The concentration of the purified DNA
was determined on the NanoDrop ND-1000 spectro-
photometer. Often the 3 mg required for hybridization
was not acquired after this first round of amplification,
so another round of amplification would be performed,
followed by purification and determination of the DNA
concentration as previously described. LM-PCR A ampli-
fication: 20 cycles followed by QIAquick PCR purifica-
tion, and then 15 cycles followed by QIAquick PCR
purification. LM-PCR B amplification: 20 cycles followed
by QIAquick PCR purification, repeated three rounds,
sequentially. Once the ChIP DNA was amplified to 3 mg,
PCR reactions of positive and negative control genes
(Supplementary Table 8) were performed with 10 ng
amplified DNA and were identical to the reactions
performed after the ChIP DNA was initially isolated.
This PCR was necessary to determine whether specificity
between the IgG or NoAb and antibody samples was
maintained after the amplification.
Labeling reaction
A total of 3 mg of amplified DNA from the antibody
sample, no antibody, or IgG sample were vacuum desic-
cated and resuspended in 2.5 ml of H2O (Sigma W4502).
4.5ml of 0.1M NaHCO3 at pH 9 was added. The DNA
was resuspended by vortexing several times. 2 ml of Cy3 or
Cy5 dye (Amersham, PA23001 and PA25001, respectively)
were added to the sample. The mix was incubated for 1.5 h
at room temperature in the dark. After incubation, 35 ml
of 100mM Na-Acetate pH5.2 was added and topped with
H2O (Sigma W4502) to a total volume of 100 ml for each
sample. The fluorescent-labeled probes were purified using
QIAquick PCR Purification kit (Qiagen 28106). The DNA
was eluted with 50 ml of EB buffer from the kit, heated to
658C. The 100 ml combined ChIP and no antibody samples
were vacuum desiccated using a SpeedVac for 60min at
maximum heat.
DNAmicroarray hybridization
The mixed DNA was resuspended in 5 ml of H2O and
mixed with 85 ml hybridization mix [100ml of DIG Easy
Hyb solution (Roche 603 558), 5 ml of 10mg/ml calf
thymus DNA (Sigma D8661), 5 ml of 10mg/ml yeast
tRNA (Invitrogen 15401-029)]. The resulting solution
was incubated at 658C for 2min, then cooled to room
temperature and applied to a CpG island array slide
(UHN Microarray Centre HCGI12K, design is available
at www.microarrays.ca) and incubated overnight at 428C
in a hybridization chamber.
Microarray washing
After hybridization, the microarray slide was washed
once with washing buffer 1 (1 SSC, 0.1% SDS) at
508C for 5min. This was followed by a wash with washing
buffer 1 (room temperature for 5min) and two washes
with washing buffer 2 (0.2 SSC for 5min) and one
final wash with washing buffer 3 (0.1 SSC for 5min at
room temperature). The slide was then dried by spin-
ning at 700 r.p.m. for 15min. To preserve the Cy5 dye
from ozone-dependent degradation, which was observed
during the summertime when the hybridization occurred,
the slides were then dipped in DyeSaver 2 (Genisphere
Q500600) and allowed to air dry.
Microarray scanning
The microarray slides were scanned using a Gene Pix
4000B scanner (Axon Instruments) at multiple PMT
voltages.
Validation using agilent promoter arrays
The Chromatin Immunoprecipitation of HL60 cells was
performed as described above. In this case, the sonica-
tion was performed as follows, 11 pulses (setting high,
26 s per pulse, 26 s on ice between pulses) from a Model
Diagenode BioRuptor Sonicator (Diagenode, BioRuptor
200, UCD-200 TM-EX) to generate fragments between
500 and 1000 bp. The immunoprecipitations were per-
formed using 0.7 mg normal rabbit IgG (Santa Cruz
Biotechnology sc-2027) or N262 home-made purified
antibody as described above. The WGA was performed
following a protocol described by O’Geen et al. (29).
This method efficiently primes the DNA fragments to
generate a library of DNA fragments with defined 30 and
50 termini. The library is then replicated using linear
amplification in the initial steps followed by a limited
round of geometric amplifications. Entire ChIP samples
with an average size of 500–1000 bp of DNA fragments
were used for the library generation and subsequent
amplification. For the library preparation and the ampli-
fication (round 1), GenomePlex Complete WGA kit was
used (Sigma WGA2) as follows. Library Preparation step:
2 ml of Library Preparation Buffer was added to the ChIP
material that has been concentrated to 10 ml. One micro-
liter of Library Stabilization Solution was added and
heated at 958C for 2min in a thermal cycler and immedi-
ately cooled on ice. One microliter of Library Preparation
Enzyme was added and incubated in a thermal cycler
precooled to 168C (168C for 20min, 248C for 20min,
378C for 20min, 758C for 5min). Amplification step
(round 1): the following master mix was added to each
sample prepared on the previous step, 7.5 ml of 10
Amplification Master Mix, 47.5 ml of nuclease-free H2O
and 5 ml of WGA DNA Polymerase. Samples were incu-
bated in a thermal cycler (958C for 3min, then 14 cycles of
948C for 15 s, and 658C for 5min). Samples were then
purified using QIAquick PCR Purification kit (Qiagen
28106). A 10 ng of each amplified sample was tested for
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specificity as described above under the PCR title. For
the reamplification step (round 2), GenomePlex WGA
amplification Kit was used (Sigma WGA3). A master
mix of 7.5ml of 10 Amplification Master Mix, 47.5ml
of nuclease-free H2O and 5 ml of WGA DNA Poly-
merase was added to 15 ng of purified amplification
product previously diluted in nuclease-free H2O to 10 ml
volume. Samples were then purified using QIAquick PCR
Purification kit (Qiagen 28106). Amplified sample (10 ng)
was tested for specificity as described above. WGA ampli-
fied DNA (4 mg) was hybridized to Agilent 2x244 pro-
moter arrays at the UHN microarray center (Toronto,
Canada). Based on our previous results a single batch of
arrays was used with lot number 19 585. Arrays were
labeled using the Agilent Genomic DNA Labelling Kit
and hybridized using the aCGH Hybridization Kit fol-
lowing the ChIP-on-chip v10 protocol as follows: for
each 1x244 promoter array, 2 mg of DNA was brought
to 26 ml final volume. A 5 ml of Random Primers (supplied
with Agilent Genomic DNA Labeling Kit PLUS) was
added and the mix was incubated at 958C for 3min,
then on ice for 5min. The 31 ml were mixed with the Label-
ing Mix to a final volume of 50 ml (10 ml of 5 Buffer, 5 ml
of 10 dNTP, 3 ml of 1mM Cyanine 3-UTP or 1mM
Cyanine 5-dUTP, 1 ml of Exo-Klenow fragment) and incu-
bated at 378C for 2 h. The enzyme was then inactivated at
658C for 10min. The labeled Genomic DNA was cleaned
with Microcon columns (Millipore, Microcon YM-30)
and eluted with 80.5 ml of 1 TE. A 5 mg Cy5-labeled
and 5 mg of Cy3-labeled DNAs were combined in a total
volume of 158 ml. The 158 ml were mixed with 50 ml of
1mg/ml of Human Cot-1 DNA, 52 ml of 10 Agilent
Blocking Agent, 260 ml of 2 Agilent Hybridization
Buffer. Samples were heated at 958C for 3min, and then
incubated at 378C for 30min. A 490 ml of the sample were
applied to the 1x244 promoter array assembled in a cham-
ber and incubated in a rotisserie hybridization oven at
658C and 20 r.p.m. for 40 h. After hybridization the micro-
array slide was washed with Oligo aCGH/ChIP-on-chip
Wash Buffer for 5min at room temperature, followed by
a wash for 5min at 318C. QC metrics used were based
on the ChIP-on-chip requirements and no arrays were
removed or repeated.
CpG island microarray data preprocessing
Array images were first manually examined for image
artifacts, then quantitated using GenePix Pro (v6.0.1.27).
A scan that maximized the dynamic range without
saturating high-intensity signals was selected and car-
ried forward for analysis. This scan was quantified using
the ‘circular’ segmentation algorithm, then preprocessed
using the variance-stabilizing normalization algorithm
(VSN). VSN was implemented in the R statistical envi-
ronment (v2.4.1) in the BioConductor open-source pro-
ject (39). Version 1.12.0 of the vsn package was used,
with print-tip groups used as strata, and default para-
meterization except for using 1000 iterations for fitting
(increased from the default of 10). All raw and proces-
sed have been made publicly available in the GEO
repository at NCBI with IDs GSE8447, GSE8448, and
GSE8449.
To test for differential hybridization, we used general
linear modeling, as implemented in the limma package
(v2.9.13) (40) of the BioConductor open-source library
(39) for the R statistical environment (v2.4.1). First, a
spot-wise linear model was fit separately to each major
design parameters: array batch, hybridization date
and dye-status. No interaction terms were included.
A Bayesian moderation of standard error was employed
following model-fitting (40). A Gaussian kernel density
was then fit to the effect estimates to compare the relative
magnitudes of these design parameters. Next, a spot-wise
linear model was fit comparing the hybridizations using a
commercially available antibody to those using a locally
produced one. The top 100 spots from each analysis were
identified, and the pair-wise P-values plotted to identify
trends in antibody specificity. A similar analysis was
performed for purified and nonpurified locally produced
antibody hybridizations. All model-fitting again employed
the limma package (v2.9.13). To compare different ampli-
fication methods we fit separate linear models to the
amplified versus nonamplified comparisons for each
amplification method. The number of differentially
bound spots between the two samples was calculated
across the entire range of naı¨ve P-value thresholds from
0 to 1, at 0.00 001 unit resolution. A similar analysis was
used to investigate hybridization order, except that the
models were fit simultaneously and the effect of each
hybridization order was extracted separately using a con-
trast matrix. An identical tiling across P-values was used,
in this case in the range 0 to 0.10 with a resolution of
0.0001. These analyses were performed in R (v2.4.1).
All gene-lists presented are based on a P-value threshold
of P< 0.05.
Agilent promoter microarray data preprocessing
Microarray data was scanned using the Agilent Feature
Extraction Software (v9.5) and then loaded into the R
statistical environment (v2.6.2) using the limma package
(v2.12.0). Array data was preprocessed using variance-
stabilizing normalization, as above, with 1000 iterations
to generate highly robust results on these large arrays.
Preprocessing employed the vsn package (v3.2.1) in the
R statistical environment. The raw and preprocessed
data were subjected to a series of quality control mea-
sures: all arrays were included in subsequent analyses.
Significance-testing used t-tests to compare the antibody
and control channels, followed by an Empirical Bayes’
moderation of standard error (40) and a false-discovery
rate adjustment for multiple-testing (41). The raw and
pre-processed data have been made available in the
GEO repository with accession GSE11245.
Spot annotation
The published array annotations for the 12k UHN
CpG island microarray were based on the UCSC build
hg17 of the human genome (38). To update these results
for the more polished hg18 build, we implemented a
new annotation algorithm using a BioPerl (v1.5.1) based
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Perl (v5.8.8) script (42). First, the 30 and 50 sequence reads
were overlapped using bl2seq (43) with a word-size of 7.
In cases where a minimum 50 bp overlap was found the
aggregated sequence was selected; otherwise the longer of
the two sequence reads was chosen. Next, the sequences
were aligned to the RepeatMasker filtered chromosomal
sequence-reads of human genome build hg18 (44) using a
locally compiled (gcc v4.1.1; AIX 5.2.0.0) NCBI BLASTN
executable with a word-size of 7 (45). The best matching
hit was selected as the most likely region of hybridization,
and the ratio of the lengths of the top two hits was used
as a measure of the likelihood of cross-hybridization. The
Agilent default annotations were used for the oligonucleo-
tide validation experiment.
RESULTS
Our analysis of ChIP-chip design parameters was con-
ducted in the context of the genomic-binding of the well
characterized Myc oncogene in an acute myelogenous
leukemia cell line, HL60 (46). Optimization experiments
utilized 12k CpG island microarrays which contain 12 192
genomic locations, representing 5411 distinct genomic
loci (38). Validation experiments were performed using
the Agilent human promoter whole genome array set.
Antibody selection, array batch, reciprocal labeling and
inter-day processing
Our first series of experiments focused on assessing four
key parameters of the ChIP-chip assay. Antibody selection
was considered first because the immunoprecipitation step
provides the starting material for the array analyses, and
as such is a major determinant of the success of ChIP-chip
studies. Second, we addressed the effect of array batch.
This can be a major confounding variable because DNA
spotted to a microarray slide may degrade or otherwise
lose sensitivity, and even arrays printed in different print-
runs from a single spotter can show variability. Third, we
evaluated the bias introduced during the process of sample
labeling. This bias refers to intensity differences between
identical samples labeled with different dyes and can arise
in several ways, including differential incorporation effi-
ciencies for the two dyes, fluorophore degradation, as
well as photo-bleaching rates or scanner-induced bias.
Fourth, we determined whether day-to-day variations in
atmospheric ozone, technical handling, scanner calibra-
tion or other, as yet unidentified, confounders affect the
hybridization step.
To evaluate the effect of these ChIP-chip parameters,
we conducted a saturated, fully blocked experiment
(Figure 1). First, 12 independent biological replicates of
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Figure 1. Experimental design to evaluate antibody effect, array batch, reciprocal labeling and hybridization. Schematic representation of the
experimental design in which six independent biological replicates of cross-linked HL60 cells were subjected to ChIP with either commercial or
home-made antibodies raised against the N-terminal 262 residues of the Myc oncoprotein. Each sample was hybridized to individual arrays with its
matched No Ab control. Dashed arrows indicate biological replicates #2 to #5, not included in the figure for simplicity. Black arrows indicate
reciprocal labeling. Dotted lines indicate the period of seven days in which the 48 arrays were hybridized.
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cross-linked HL60 cells were subjected to ChIP with
polyclonal antibodies raised against the N-terminal 262
residues of the Myc oncoprotein. Six of the twelve repli-
cates were ChIPed using a commercial antibody and the
remaining six using a home-made antibody raised against
the identical region. For each of these twelve replicate
ChIP reaction we probed two batches of arrays separated
in print-age by about 6 months. This allows us to evaluate
the array batch effect. Each sample was hybridized twice
to each batch with reciprocal labeling. Thus, each bio-
logical replicate was hybridized to four separate arrays,
leading to 24 arrays for each antibody and 48 arrays in
total. Finally, these 48 arrays were hybridized in batches
over 7 days, allowing us to robustly estimate the effect of
date-of-hybridization (Figure 1).
To quantify the importance of antibody selection,
we compared two polyclonal antibodies raised against
the same N-terminal region of the Myc protein. One
antibody was purchased from a commercial vendor
while the other was locally produced (Figure 1). Across
the 48 arrays of our study, we observed a significant
antibody effect. When the P-values of the top-ranked
spots on the array are compared for the two antibodies,
a linear trend is observed, suggesting specificity is compar-
able (Figure 2A). However, despite equivalent replicate
numbers and full-blocking of other parameters, as
described below, P-values are distinctly lower for the com-
mercial antibody, suggesting that it results in better signal
to noise characteristics. To increase the specific activity of
our home-made antibody, we subjected it to a purification
procedure to remove contaminating serum proteins, and
compared purified and unpurified home-made antibody in
a similar fashion (Figure 2B). A linear trend was again
observed, with the purified antibody showing lower
P-values than the unpurified. Note that the magnitude
of P-values in Figure 2A and B are different because of
the different replicate numbers involved (Figure 2A,
n=24; B, n=4 for each antibody). These data suggest
that antibody purity is a key factor influencing the speci-
ficity and sensitivity of ChIP-chip studies and may
improve the performance of some antibodies.
To evaluate the effect of array batch, dye bias and inter-
day hybridization, we fit spot-wise linear models to the
results of each parameter separately and plotted the
Gaussian densities of the magnitudes of these effects
(Figure 3). These Gaussian densities are essentially
smoothed histograms. Their height (y-axis) reflects the
number of spots on the arrays affected by each parameter
at the given fold-change (x-axis). Each curve reflects
a different source of variability (dye, batch and date).
The numbers under the plot give the number of spots
affected by each parameter at a given fold-change thresh-
old. All three curves are unimodal, with a sharp peak at
the origin. This shows that the majority of spots on the
array are unaffected by each parameter. Of the spots that
are affected, the magnitude is generally very modest, in the
range of 0.5 to +0.5 log2 units. This corresponds to an
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Figure 2. Measuring antibody effect. (A) Comparison of ChIP-chip
results using a commercial and home-made polyclonal antibody
raised against the same portion of Myc protein showed a similar
linear trend and ordering by the two antibodies (P< 2.2 1016;
Wilcoxon Rank Test), however, they differed by orders of magnitude
in sensitivity (axis scales). (B) Purification of the home-made antibody
preparation improved sensitivity. The line represents equal sensitivity
(y= x). Note that orders of magnitude on the axes differ between parts
A and B because the replicate numbers are different (A, n=24;
B, n=4).
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Figure 3. Evaluating array batch effects, dye-bias and inter-day
processing. To assess the effects of array batch, dye-swap, and hybrid-
ization date we fitted separate spot-wise linear models to the data from
our study for each of these three parameters. Gaussian kernel densities
were then plotted for the coefficients of the fits for each model. Each
curve is unimodal, with a sharp peak around the origin, indicating that
most spots on the array do not vary with these design parameters. The
spot counts along the bottom of the figure further quantify the degree
of variability at several thresholds (0.5=1.4-fold, 1.0=2.0-fold,
1.5=2.8-fold, 2.0=4.0-fold).
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effect of 1.4-fold. Overall, no >10% of spots on the array
show large variability towards any of these parameters—
suggesting that both the ChIP protocol and the CpG
island arrays used are robust towards perturbations in
any of these factors.
Despite this basal similarity there are differences across
the three parameters. The curve of dye-bias (red) shows
significant asymmetry, corresponding to a consistent Cy3
bias. While only 11 spots show Cy5/Cy3 ratios of 1.4-fold
or higher, 685 spots show Cy3/Cy5 ratios of 1.4-fold or
greater. This marked asymmetry highlights the impor-
tance of balancing experiments across the two dyes used
in the study.
The effect of array batch shows a similar, but smaller
asymmetry. Older arrays consistently show lower signal
intensities than newer arrays, with 408 spots showing an
old/new ratio of at least 1.4-fold, while only 210 spots
show a new/old ratio of similar magnitude. This variabil-
ity suggests that experiments should be conducted with
arrays of a single batch, or experimental samples ran-
domized across multiple batches.
Surprisingly, the effects of hybridization date affect
almost 10% of the spots on the array, despite the same,
experienced hands conducting all hybridizations in this
series of experiments. This effect is symmetrical, with
approximately equal numbers of spots showing date-
dependent enrichment and depletion. The source of this
bias is unknown. It is possible that atmospheric ozone
may have differed from day-to-day. We and others
have experienced Cy5 squelching due to ozone (47,48).
However, in this case ozone is not likely to be the source
of the bias, as we chose to conduct these experiments
during times of consistent and low atmospheric ozone.
Variations in the efficiencies of the labeling reaction and
subsequent column-clean-up may account for this effect.
It is also possible that variation in handling at the level
of post-hybridization washes may contribute to this inter-
day variability. Another possibility is that scanner calibra-
tion varied across the course of our experiment, but the
biases described here are not temporally-dependent (data
not shown). This suggests that if scanner-calibration is an
issue, then it is a random drift rather than a progressive
degradation.
As an alternative visualization of this data, we provide
histograms of each factor as Supplementary Figure 1.
In addition, the raw and normalized data are available
in the GEO repository, while the linear model fits are
available as Supplementary Tables 1–3.
Amplification method
Sufficient DNA for microarray hybridization cannot
usually be obtained from a single ChIP reaction. The
amount required can be achieved by pooling multiple
ChIP reactions (12), but this approach is expensive and
labor intensive. Further, when dealing with biologically
limited samples, such as primary patient material,
repeated ChIPs may not be possible. Indeed in such
cases pooling multiple ChIPs may introduce intra-sample
heterogeneity (49). To overcome this rate-limiting step, the
precipitated DNA in a single ChIP reaction is usually
amplified. A variety of PCR-based methods exists, includ-
ing LM-PCR, WGA, random primed PCR (RP-PCR) and
T7 primed PCR methods.
We develop an assay to evaluate the bias introduced by
amplification protocols. For each amplification protocol
we take a pool of total genomic DNA and amplify one
aliquot. We then hybridize equal amounts of amplified
and unamplified DNA on a microarray slide. This proce-
dure is repeated to determine the number and nature of
the spots showing amplification bias (Figure 4A). Using
this method we tested the three most common amplifi-
cation techniques employed in ChIP-chip experiments,
RP-PCR, WGA and LM-PCR (Figure 4A). To consider
parameter sensitivity for the LM-PCR method we evalu-
ated protocols with low (LM-PCR A, 45 cycles) and high
(LM-PCR B, 60 cycles) PCR cycle number.
For each amplification method, we considered the
fraction of spots on the array that showed altered hybrid-
ization between amplified and unamplified samples
as a function of the p-value threshold (Figure 4B).
Methods with reduced amplification bias will show lower
curves, especially at experimentally relevant lower P-value
thresholds (Figure 4B, inset). The LM-PCR A and WGA
amplification methods alter the hybridization of many
fewer spots than either RP-PCR or LM-PCR B. These
data demonstrate a practical and affordable method of
evaluating a variety of amplification protocols using
genomic DNA.
Hybridization control
A variety of different hybridization controls have been
used for ChIP-chip studies. For example, some groups
have employed a ‘no antibody’ control (12), while others
have used total genomic DNA (11,50). To determine if
there are significant differences between these hybridiza-
tion controls, we designed a series of experiments to test
each approach (Figure 5A). Specifically, we compared
direct hybridization of ChIP samples against a mock
treated control (Direct No Ab) and against an IgG
antibody control (Direct IgG). We also considered the
use of total input DNA as a ‘denominator’ by hybridizing
ChIP and IgG samples separately against total-input
DNA (Indirect No Ab), then comparing their intensities
indirectly during statistical analysis by using a linear
model. The results (Figure 5B) are surprisingly invariant
from one control to the next, and at any given P-value
the number of hits identified in each experiment is nearly
identical. Nevertheless, the two direct designs show more
sensitivity than the indirect approach in a threshold-
independent manner.
Validation studies
To evaluate the optimized parameters determined above,
we conducted a new Myc ChIP-chip experiment with
them. Thus, we used a purified antibody for the ChIP
reaction, DNA was amplified by LM-PCR, we hybridized
a single CpG island array batch from a recent print
run, and IgG was used as the hybridization control.
Dye swaps were randomized across hybridization dates,
and the entire experiment was conducted at high
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replication (n=13). By using this highly optimized design,
we expected to both minimize bias and increase speci-
ficity. Following preprocessing and statistical analysis of
the raw data we obtained a list of 534 Myc bound spots
(Supplementary Table 4). This represents 9.9% of the
5411 distinct genomic loci represented on this array plat-
form (38). Importantly, 35 of these 535 spots correspond
to known Myc targets annotated in the Myc target gene
database (51), providing strong support for the validity of
this gene list.
To further generalize our results, we then performed
a second validation experiment using a different micro-
array platform—Agilent genome-wide oligonucleotide
promoter arrays. We again employed our optimized
parameters, using a purified antibody, a single batch of
arrays and IgG as a hybridization control. For this
second validation, we used the WGA method to amplify
the DNA. As these oligonucleotides are a relatively new
platform we rigorously evaluated array quality and found
no evidence of spatial or distributional artifacts (data not
shown). Following preprocessing and statistical analysis
we obtained a list of 53 453 genomic regions that bind
c-Myc, corresponding to 10 196 unique genes or genomic
features (Supplementary Tables 5 and 6). This represents
11.1% (53 453 of 481 909) of the unique genomic regions
and 28.9% of the unique genes represented on the array,
indicating wide-spread Myc binding. On average each
unique gene was represented by 5.24 probes, giving a
high-degree of internal replication within the array.
Comparison of the CpG island and promoter arrays
is confounded by the lack of perfect correspondence
between the genomic features represented on each array.
For example, the CpG island arrays might interrogate
a region downstream of the transcriptional start-site,
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Figure 4. Comparing DNA amplification methods. To evaluate
whether specific DNA amplification protocols introduce different
degrees of bias, we surveyed the genome-wide effects of three amplifi-
cation protocols. (A) Total genomic DNA was amplified with one of
four different protocols: random priming (RP-PCR), WGA and two
LM-PCR protocols (LM-PCR-A and LM-PCR-B). The resulting
DNA was then hybridized to a CpG Island microarray against an
equal amount of unamplified total genomic DNA. This procedure
was repeated four times for each of the three amplification methods,
and the raw data was pre-processed with VSN and model-based t-tests
(see Materials and methods section). Black arrows indicate reciprocal
labeling. (B) The fraction of spots on the array that are differentially
amplified (fraction of spots called) is plotted against the P-value thresh-
old for each amplification method. The y-axis gives the fraction of
spots differentially amplified, thus a value of 0.1 indicates that 10%
of the spots on the array have been affected by the amplification
protocol. The y= x line reflects the fraction of spots that would be
expected to be altered by amplification by chance alone. All four curves
lie above this line, demonstrating the large effect of amplification. The
curves for LM-PCR A and the WGA lie below that of the other two
methods for all P-values, demonstrating that these two methods intro-
duce the smallest amplification bias amongst the four protocols tested.
The inset provides a zoom-in of the P-value range from 0 to 0.1, where
thresholds for most experiments are selected.
B
A Direct NoAb
Ab
No Ab
Direct IgG
Ab
IgG
Indirect NoAb
Ab NoAb
TI
Pe
rc
en
ta
ge
 o
f S
po
ts
0.00
0
2
4
6
0.01 0.02 0.03 0.04 0.05
P-Value
Figure 5. Comparing hybridization controls. A number of potential
control samples can be used for ChIP-chip studies. (A) Three
common approaches were compared, including two direct hybridization
approaches (No Ab and IgG) and an indirect hybridization approach
(No Ab). For each approach ChIP-chip studies of Myc in HL60 cells
were performed. Black arrows indicate reciprocal labeling. (B) The
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while the promoter array interrogates one upstream of the
start-site. Nevertheless, we compared the hits from the
CpG island array that were within 10 kb of an annotated
Entrez Gene transcriptional-start site to those from the
promoter array. Fully, 81% (208/256) were confirmed
on the promoter arrays at a 10% FDR. Some fraction
of the unconfirmed cases are attributable to differences
in the genomic regions interrogated, indicating that
inter-platform variability is at most 19% in this study.
Surprised at the very large fraction of promoter regions
that exhibited c-Myc binding in our genome-wide analysis,
we sought to validate these results using gold-standard
Q-PCR on independent biological replicates. We selected
50 random genomic loci from our gene-lists (Supplemen-
tary Tables 4–6) and primer pairs to interrogate them by
Q-PCR. We used three Myc ChIP biological replicates
in HL60 cells that were completely separate from any of
the samples used in either the optimization or validation
studies. As a negative control we employed a region of
chromosome 6 that showed no evidence of Myc binding
in the ENCODE study. Our Q-PCR results (Figure 6 and
Supplementary Table 7) verify the extensive binding of
0
1
2
3
4
5
TCERG
1
CHD9
NO
L6
UTP18
UQCRFS1
LR
PPRC
K
LC4
PO
LR3A
THO
C1
PO
LG
TR
FP
M
PHO
SPH10
R
PL34
R
PL34
CDC14A
TR
FP
SLC1A5
CDC14A
M
PHO
SPH10
K
LC4
R
A
D
51
CDCA2
VD
P
D
ICER1
ASCC3
chr6
0
1
2
3
4
5
ASCC3
R
A
B33A 
PO
LR3A
PH
LPP
R
A
E1
ASCC3L1
PLTP
R
A
B3C
SHF
G
DAP2
ASCC3L1
G
AS1
H
IST1H1B
IL1A
D
LL1
LTK
CHD2
O
G
G
1 
SHH
FN
B
P1
VEG
FB
PK
IB
TR
H
PA
B
PC5
R
LN
2
chr6
lo
g2
|M
yc
/Ig
G|
lo
g 2
|M
yc
/Ig
G|
Figure 6. Myc recruitment to regulatory regions of novel target genes in growing HL60 cells. ChIP assays with antibody to Myc and IgG control
antibody from exponentially growing HL60 cells. DNA was Q-PCR amplified by using primers against 50 distinct genomic regions. A negative
control region on chromosome six that showed no Myc binding in any cell-line of the ENCODE study was also included and is shown twice for
reference purposes only. This region is shaded in black and is labeled ‘chr6’. Each column represents a specific region, identified by the HGNC gene-
symbol. When two different regions of the same gene were tested, the same gene can be found twice in the figure (Supplementary Table 8). The y-axis
gives the mean log2|Myc/IgG| values for each genomic region. Error bars represent SDs.
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c-Myc in HL60 cells, with an overall validation rate of
45/50. Further, the array and PCR results are highly
correlated on a region-by-region basis, both in terms
of statistical significance (Spearman’s rho=0.533,
P=7.80 105) and magnitude of enrichment (Spear-
man’s rho=0.598, P=5.77 106). These data show
that our optimized ChIP-chip experimental parameters
allowed us to identify novel bona fide Myc target genes
using two separate microarray platforms as well as quan-
titative PCR.
DISCUSSION
ChIP-chip is a relatively new technology that has quickly
become a standard method for screening protein–DNA
interactions in vivo. However, it is also a highly complex
method, with many tunable parameters. We set out to
systematically test a large subset of these experimental
design parameters. Many previous studies of microarray
reproducibility have employed spike-in or mixture designs
(23,31,33,35), but it is unclear if spike-in or mixture exper-
iments reproduce the underlying complexity of real bio-
logical samples. Accordingly, we chose to focus on a
biologically well-characterized system: involving the Myc
oncogene as a regulator of gene transcription in the HL60
human myeloid leukemia cells (12).
The first experimental design parameter considered
was the influence of different antibodies on the results of
a ChIP-chip study. Intuitively, the nature of the anti-
body is a limiting step for ChIP-chip studies. To put a
lower bound on the variability introduced by different
antibodies we selected two polyclonal antibodies raised
against the same portion of the Myc protein (the
N-terminal 262 residues, N262) but derived from different
sources. Critically, the two antibodies showed a broadly
linear, well-ordered trend (P< 2.2 1016; Wilcoxon
Rank Test), but differed significantly in sensitivity
(Figure 2A). We subjected the lower sensitivity antibody
to a column purification procedure to remove contami-
nating serum proteins, and this purification procedure
significantly improved performance (Figure 2B). Clearly,
antibody selection is a critical element of ChIP-chip
studies, and antibody-specific activity is an important
parameter to consider prior to hybridization.
Next, we considered the effects of inter-batch variability
of the CpG island microarrays. This array platform has
been widely used by other groups (27,50,52), giving con-
fidence in its reliability. We tested the variability between
two batches of arrays and observed a consistent bias in
signal-intensity, with the older array batch showing lower
signal (Figure 3). This bias is highly reproducible, as we
analyzed 24 arrays from each batch. The bias is sym-
metric, and therefore can lead to both false positives
and false-negatives. Fortunately, straightforward methods
exist to control this bias. First, whenever possible, arrays
from a single batch should be used. Second, when multiple
batches are used samples should be randomized across
batches. Third, linear-modeling methods can be used to
explicitly account for and remove batch variability. The
first two methods are standard experimental design
practices, while the third has been successfully used in
the analysis of mRNA expression array data (53).
Third, we considered the effects of reciprocal labeling
(dye-swapping) a single sample with the Cy3 and Cy5
dyes. This topic has been extensively studied from both
theoretical (54,55), and empirical (56) perspectives. These
studies found small, but consistent effects of reciprocal
labeling. While reciprocal labeling has been shown to
have less experimental value than true biological repli-
cates, they appear to carry more information than
simple repeated measures (56). Very moderate effects of
reciprocal labeling were observed, affecting only about
0.1% of the spots on the array at a two-fold change
level (Figure 3). There are many more spots affected by
dye status at a less stringent 1.4-fold change threshold,
however changes of this magnitude introduce a much
smaller risk of altering the spot-wise statistical analyses.
This indicates that, at least for ChIP-chip with our CpG
island arrays, reciprocal labeling is not necessary and
dye-bias is a negligible confounder. Nevertheless, it
seems prudent to randomize samples across dye-status
to account for unanticipated dye-bias in specific experi-
mental scenarios, especially because of the profound
asymmetry in this parameter.
The fourth experimental parameter considered was
the effect of hybridization date. Because our experiment
was fully blocked across all factors, we were able to
directly estimate the effects of this parameter with a
linear model. We were surprised to find that the day on
which hybridization was performed had a greater influ-
ence on the final results than either the batch of arrays
or the use of dye-swaps (Figure 3). The sources of this
bias are unclear. The symmetrical distribution of the
effect suggests that neither ozone-status nor scanner
settings are a major factor, suggesting random drift
within the scanner. Perhaps use of a mechanical hybridi-
zation and wash station would decrease inter-day varia-
bility, although this variability may also result from the
labeling reaction or the subsequent column clean-up
procedure. Control of this factor is straightforward:
samples should be randomized across experimental day,
so that biological replicates of a given condition are
hybridized on different days.
The fifth experimental parameter considered was
the method of DNA amplification. While the antibody-
based ChIP protocol imparts specificity and sensitivity
to ChIP-chip experiments, the quantity of DNA necessary
for hybridization cannot usually be obtained in a single
ChIP. Two basic strategies have evolved to cope with
this issue: pooling of multiple ChIPs (12) and amplifica-
tion of ChIP DNA (26). A variety of different PCR-based
amplification methods have been developed and are in
use by different groups. Assessing the performance of
these methods has been challenging. To directly compare
an amplified ChIP sample to an unamplified ChIP
sample requires the pooling of a large number of ChIPs
for each replicate, resulting in significant costs, time and
labor. Further, care must be taken in the experimental
design to ensure that the reduction in variance that
results from pooling ChIP reactions does not confound
the effects of the amplification procedure. As a result
PAGE 11 OF 14 Nucleic Acids Research, 2008, Vol. 36, No. 21 e144
of these financial and technical factors, only one study has
assessed the performance of amplification methods for
ChIP-chip data (23), although several such studies do
exist for mRNA experiments (57,58) where a much
larger amount of starting material is readily available.
To resolve this issue, we have developed a novel approach
that hybridizes amplified against non-amplified geno-
mic DNA (Figure 4A). We evaluated four amplification
protocols: RP-PCR, WGA and two variations of LM-
PCR. Because of its simplicity, this procedure could be
readily repeated and an n=4 was generated for each
amplification procedure. The number of spots found to
be differentially hybridized between the matched ampli-
fied and unamplified samples is a measure of ampli-
fication bias (Figure 4B). Interestingly, the performance
of random-priming falls in between that of the two
LM-PCR protocols, indicating that specific parameter
choices within a protocol are important for determining
overall performance. The WGA and low-cycle LM-PCR
protocols showed similar performance, suggesting that
one of these methods should be selected to minimize
amplification bias. Our method of comparing amplifica-
tion procedures provides a new way to measure variabil-
ity, independent of antibody or biological question, at a
reasonable cost.
The final experimental design parameter considered
was the selection of a negative control for hybridization
to the array. We considered three approaches (Figure 5A),
including two direct and one indirect method. For each
method we performed four Myc ChIP-chip experiments
in HL60 cells. When we compared the sensitivity of
these methods (Figure 5B) the two direct methods
performed comparably, with no significant differences
between the IgG and no-antibody controls. The indirect
design, however, did show reduced sensitivity at any given
P-value. Thus, direct designs, which use half as many
arrays as indirect designs, are favored for both cost and
sensitivity.
Having extensively optimized these six parameters, we
set up two Myc ChIP-chip experiments to test our optimi-
zation in an integrated way. Our first experiment used
extensive biological replication (n=13) on CpG Island
arrays, while our second used lesser replication (n=5)
on much larger whole-genome oligonucleotide promoter
arrays. To validate the results of these two studies we
employed Q-PCR using biologically independent samples.
Of the 50 unique primer sets we analyzed, 45 were vali-
dated, for a success rate of 90%. This strong evidence that
the vast majority of the 10 196 genomic locations found to
be associated with Myc in HL60 cells are true positives.
Importantly, we showed that the validation rate remained
high in the bottom portion of our list. This suggests that
the statistical analysis was conservative, and that addi-
tional hits might be uncovered by relaxing our P-value
threshold from 0.05 to 0.10 or higher. This is particularly
important because many published ChIP-chip studies use
a P-value threshold of 0.001, 50 times more stringent than
used here (11). Overall, our extensive validation confirms
the success of our parameter optimizations.
Over the past decade, a series of studies from multi-
ple groups characterized the major experimental design
parameters for mRNA expression studies (33,56,59–61).
A common theme of these studies is that it is necessary
to use both empirical and statistical methodologies to
optimize the experimental design. We have provided
the first comprehensive overview of experimental design
parameters for ChIP-chip data, testing both parameters
related to all microarray experiments and those unique
to ChIP-chip studies. We find good concordance of
ChIP-chip and mRNA expression design characteristics.
For example, in both cases, indirect hybridization designs
appear to be more costly without providing a significant
advantage over simpler direct designs. Similarly, we have
shown that biological replicates are more important than
dye-swaps, just as identified for mRNA expression arrays
(56). We also demonstrated that antibody characteristics
and amplification methods are major sources of variabil-
ity in ChIP-chip studies. For example, using an antibody
of maximal specific activity appears to be critical for
increasing the sensitivity of ChIP-chip studies. In addition,
we introduced a novel method for testing amplification
bias in an antibody-independent manner. This study indi-
cated that amplification procedures can significantly bias
ChIP-chip results, and provides a simple, efficient method
for benchmarking the bias of specific amplification
protocols.
Our findings also raise a number of intriguing questions
surrounding the antibody and amplification results. We
demonstrate that antibody-specific baseline variability
exists in ChIP-chip studies, and that while it can be miti-
gated it cannot be completely removed. It would be of
great interest to replicate these studies with monoclonal
antibodies, or polyclonal antibodies raised against dif-
ferent regions of a protein. In this manner, it might be
possible to identify characteristics that predict which
antibodies will be most sensitive or specific in a ChIP-
chip study. Alternatively, this may not be a generalizable
parameter and may be protein-specific. Similarly, we
have presented a novel technique for studying amplifica-
tion bias, and identified both a variant of LM-PCR and
the WGA protocol as most favorable in this regard.
Nevertheless, all amplification protocols tested here intro-
duced a significant amount of bias. Our strategy for bias-
identification should prove useful in the development of
reduced-bias amplification protocols.
All of our analyses were performed studying the c-Myc
transcription factor in the HL60 cell line. While this
results in a consistent comparison across our many exper-
iments, this also means that our results are formally
restricted to a single biological system. However it is
highly probable that our findings can be widely general-
ized. First, our validation experiment used a separate
microarray platform with widely different feature sizes
and again found a high confirmation rate by Q-PCR.
Second, several of the parameters studied here are
common to many microarray studies, including the
choice of amplification method and the inter-batch
and inter-day variability of microarrays and scanners.
In particular, our analysis of amplification is relevant
to studies of genomic variation using array-CGH and
SNP-arrays. Third, the quality of antibody used in ChIP
reactions will affect the quality of data retrieved by
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microarray, PCR and sequencing-based techniques. Thus
we expect these findings to be broadly applicable to
many fields.
As ChIP-chip studies continue to broaden in the scope
and detail of the biological questions they probe, the
application of optimized and validated experimental
designs will be a significant advantage to the field.
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